Aletheian Wealth Advisors LLC Has $416,000 Stake in Johnson & Johnson (NYSE:JNJ)

Aletheian Wealth Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 63.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,511 shares of the company’s stock after buying an additional 972 shares during the quarter. Aletheian Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $416,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $290,000. Capital & Planning LLC increased its position in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock valued at $221,000 after acquiring an additional 183 shares during the last quarter. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Union Bancaire Privee UBP SA purchased a new position in Johnson & Johnson in the fourth quarter worth $85,886,000. Finally, Curbstone Financial Management Corp grew its stake in Johnson & Johnson by 1.1% in the 4th quarter. Curbstone Financial Management Corp now owns 26,732 shares of the company’s stock valued at $3,866,000 after purchasing an additional 280 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $154.99 on Friday. The business’s fifty day moving average is $154.31 and its 200 day moving average is $153.65. The firm has a market cap of $372.92 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s payout ratio is 57.84%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Finally, Barclays reduced their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.